# OnCo record geometry-mono-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/geometry-mono-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "geometry-mono-1", "NCT02414139" ;
  schema:name "GEOMETRY mono-1"@en ;
  schema:description "GEOMETRY mono-1 showed that capmatinib shrinks two thirds of untreated lung cancers with a MET exon 14 skipping mutation and about four in ten after chemotherapy, which made MET exon 14 the seventh lung cancer driver with an approved targeted drug."@en ;
  schema:url <https://onco.cc/trials/geometry-mono-1/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02414139>, <https://doi.org/10.1056/NEJMoa2002787> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/crizotinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/met-amplification/> .